Features

07 Aug 07

Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago.
Olwen Glynn Owen

30 Jul 07

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen

25 Jul 07

Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus

24 Jul 07

The best selling blockbuster drug in 2006 was atorvastatin from Pfizer and Astellas Pharma with ww sales of US$ 13.6 bln. Biologics made 23.1 % of the total blockbuster drug sales of US$ 233.7 bln generated by 114 blockbuster drugs from 30 companies.
Pau Cuevas

20 Jul 07

First medicine shown to extend survival of previously untreated lung cancer patients beyond one year.
Erica Bersin

02 Jul 07

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington

12 Jun 07

This free report looks into the huge opportunities and challenges available to pharmaceutical companies when it comes to increasing sales force effectiveness in the Asia-Pacific region. Download the report here - http://www.eyeforpharma.com/sfeapac/report.shtml
Lisa Roner, eyeforpharma

11 Jun 07

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen

11 Jun 07

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor

08 Jun 07

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen

05 Jun 07

In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
Lhasa Limited

04 Jun 07

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen

30 May 07

The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio
La Merie Business Intelligence

30 May 07

The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio
La Merie Business Intelligence

23 May 07

In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
Paula Mumby

22 May 07

With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
Paul Hartigan

14 May 07

Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
Naseem Javed

04 May 07

June 3 - 7, 2007 Indiana Convention Center, Indianapolis, Indiana, USA Members of the Lhasa Limited sales team will be attending this year’s ASMS sponsored Annual Conference on Mass Spectrometry and Allied Topics. The event is attended by almost 6,000 scientists and over 2,000 papers are presented alongside posters and talks.
Marketing Team

02 May 07

Sales of statins have reached a plateau, the imminent decline may be slowed by combination with cholesterol absorption inhibitors; future direction of R&D is focused on increasing HDL cholesterol.
La Merie Business Intelligence

25 Apr 07

The biogenerics industry consolidates with Indian players emerging in Western countries; pegylation, protein engineering, drug delivery and oral small molecules feed the pipeline of next generation competitors of therapeutic proteins
La Merie Business Intelligence

20 Apr 07

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
Paul Hartigan

11 Apr 07

The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007
Richard Bracchi

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

03 Apr 07

PharmiWeb Solutions – online publisher and e-business solutions provider to the pharmaceutical sector – recently announced the results of its inaugural PharmiWeb.com Annual e:HR Europe Awards.
Mike Wood

23 Mar 07

SYDNEY, N.S.W., 2 Mar 2007 – The recently released GenericsWeb Pipeline Developer patent report for Levitra® (Vardenafil) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s lifecycle.
Leighton Howard

20 Mar 07

Covering all the major topics surrounding EDC and other e-Clinical technologies, this year’s e-Clinical Trials event will also look carefully at how to integrate a range of systems for a successful e-Clinical programme and bring you up-to-date on current standards and the latest technological options. Delegates will also benefit from a highly detailed interactive workshop on managing e-Clinical Trials in exotic and difficult locations. Furthermore, This year’s e-Clinical Trials conference wil
Amir Sebahat

08 Mar 07

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug
La Merie Business Intelligence

01 Mar 07

Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field.
La Merie Business Intelligence

26 Feb 07

Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %).
La Merie Business Intelligence

14 Feb 07

The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of the field
La Merie Business Intelligence